Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05064735 · ClinicalTrials.gov registry record · Phase 3
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 407
- Enrollment target
- 20
- Study locations
NCT05064735 is a Phase 3 study of Obesity that has completed, run by Novo Nordisk A/S. The registered enrollment target is 407 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT05064735, a Phase 3 study of Obesity, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 407 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pain in the knee in people taking semaglutide with people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. During the study, participants will have talks with study staff about how to eat healthy food and how to be more physically active. The study will last for about 1 ½ years. Participants will have 14 clinic visits with the study staff. At the first clinic visit participants will have a blood sample taken. Participants will have an X-ray of participants knee taken at the first visit. If participants have had an X-ray recently, this may not be needed. At 6 of the clinic visits participants cannot take pain medications for 3 days before the visit. Participants cannot take part if participants have had a joint replacement surgery in participants knee. Participants cannot take part if participants have or have had diabetes. Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Conditions Studied
Interventions
- DRUG semaglutide 2.4 mg
- DRUG semaglutide 2.4 mg (placebo)
Study Locations (20)
California
- Anaheim Clinical Trials, LLC - Anaheim
- Stuart L. Silverman MD - A Medical Corporation - Beverly Hills
- Valley Research - Fresno
- Providence Medical Foundation - Fullerton
- Desert Oasis Hlthcr Med Group - Palm Springs
- Encompass Clinical Research_Spring Valley - Spring Valley
- Diablo Clinical Research, Inc. - Walnut Creek
Florida
- Clinical Research of Hollywood_Hollywood - Hollywood
- Westside Center For Clinical Research - Jacksonville
- Jacksonville Ctr For Clin Res - Jacksonville
- Well Pharma Medical Research Corp - Miami
- Renstar Medical Research - Ocala
- Clinical Trial Res Assoc,Inc - Plantation
Illinois
- Clinical Invest Special_Gurnee - Gurnee
- Evanston Premier Hlthcr Res - Skokie
- Clinical Invest Special_Gurnee - Wauconda
Alabama
- Baptist Health System - Montgomery
Arizona
- Ortho Arizona - Phoenix
Hawaii
- East West Medical Research Institute_Honolulu - Honolulu
Indiana
- MediSphere Medical RC - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2023-09-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05064735
The ClinicalTrials.gov registry entry for NCT05064735 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (50% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which semaglutide 2.4 mg is the first listed.
NCT05064735 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05064735 about?
NCT05064735 is a clinical study titled "Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis". This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pai...
What is the current status of trial NCT05064735?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 407 participants. The study started on 2021-10-01. Estimated completion is 2023-09-08.
What conditions does trial NCT05064735 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT05064735?
The interventions under investigation include: semaglutide 2.4 mg (DRUG), semaglutide 2.4 mg (placebo) (DRUG).
Who is sponsoring clinical trial NCT05064735?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05064735 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.